|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 600 Massachusetts Ave, NW |
Address2 | SUITE 300 |
City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
|
5. Senate ID# 15920-12
|
||||||||
|
6. House ID# 314640000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Raymond Gill |
Date | 4/19/2019 9:36:43 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R.1892, Bipartisan Budget Act of 2018
H.R.1625, Consolidated Appropriations Act, 2018
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019;
H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245)
S. 3158, Department of Labor , Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019;
H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020
- Issues related to FDA and HHS program funding for the FY19 Labor, HHS, Education and Related Agencies, and FY19 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Andrew |
Womack |
|
|
|
Matthew |
Sulkala |
|
|
|
Catherine |
Phillips |
|
|
|
Elise |
Conner |
|
|
|
Vanessa |
Gannon |
|
|
|
Brian |
Maloney |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S.3738 - Hatch-Waxman Integrity Act of 2018
- Intellectual property and process patent issues
- Patent litigation reform
- IPR process
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Catherine |
Phillips |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act
S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act
S. 2453 - Ensuring the Value of the 340B Program Act of 2018
HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals
HR 5598 - 340B Optimization Act
HR 2889 - Closing Loopholes for Orphan Drugs Act
HR 6240 - Drug Discount Accountability Act (user fees)
H.R.6071 - SERV Communities Act of 2018
S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017
P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA)
S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018
S.974 - CREATES Act of 2017
H.R. 2113 - The Prescription Drug STAR Act
H.R. 1520, the Purple Book Continuity Act;
H.R. 1503, the Orange Book Transparency Act;
H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and
H.R. 965, the CREATES Act;
- Issues related to the 340B Drug Discount Program
- Issues relating to drug pricing
- Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives.
- Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety, and counterfeiting, and biosimilars.
- General education about policies impacting pharmaceutical development, approval, reimbursement, and pricing.
- Issues related to healthcare legislation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Andrew |
Womack |
|
|
|
Matthew |
Sulkala |
|
|
|
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Brian |
Maloney |
|
|
|
Vanessa |
Gannon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act)
S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act
S. 2453 - Ensuring the Value of the 340B Program Act of 2018
Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018).
HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals
HR 5598 - 340B Optimization Act
HR 2889 - Closing Loopholes for Orphan Drugs Act
HR 6071 - SERV Communities Act
HR 6240 - Drug Discount Accountability Act (user fees)
S.3787 - DISARM Act of 2018
H.R. 7077, the Restoring the Patients Voice Act
S.551, REFUND Act of 2019
H.R. 1520, the Purple Book Continuity Act
H.R. 1503, the Orange Book Transparency Act;
H.R. 1499, the Protecting Consumer Access to Generic Drugs Act
H.R. 965, the CREATES Act
- Issues related to Medicare and Medicaid coverage and reimbursement
- Issues related to the 340B Drug Discount Program
- Issues related to drug pricing
- Medicare reimbursement for biosimilars
- MACRA treatment and reimbursement of Part B drugs
- Medicare payments for inpatient antimicrobials
- Issues related to Right to Try
- Issues related to drug importation
- Issues related to the International Pricing Index for Medicare Part D
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Andrew |
Womack |
|
|
|
Matthew |
Sulkala |
|
|
|
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Brian |
Maloney |
|
|
|
Vanessa |
Gannon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R.1, Tax Reform Act of 2017 (Public Law No. 115-97)
H.R.88, Retirement, Savings, and Other Tax Relief Act of 2018 and Taxpayer First Act of
- Issues related to the tax reform bill and implementation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Catherine |
Phillips |
|
|
|
Matthew |
Sulkala |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
- Issues relating to trade policy and negotiations impacting the biopharmaceutical industry
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Andrew |
Womack |
|
|
|
Catherine |
Phillips |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
- Issues related to public health protection including influenza development and preparedness
- Issues related to Right to Try
- Issues related to antimicrobial and antiviral research and product development
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Andrew |
Womack |
|
|
|
Vanessa |
Gannon |
|
|
|
Catherine |
Phillips |
|
|
|
Elise |
Conner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
- Drug pricing issues
- Prescription Drug User Fee Act reauthorization
- HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Andrew |
Womack |
|
|
|
Matthew |
Sulkala |
|
|
|
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Brian |
Maloney |
|
|
|
Vanessa |
Gannon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOR
16. Specific lobbying issues
- Issues related to Foreign Agents Registration Act (FARA including Disclosing Foreign Influence Act -H.R. 4170/S. 2039
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Catherine |
Phillips |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIN
16. Specific lobbying issues
- Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Catherine |
Phillips |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |